Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUNLUN: durvalumab with definitive chemoradiation for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600131658Phase 3Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing durvalumab + dCRT with placebo + dCRT (2 arms). Primary endpoint: Progression-free survival in patients with PD-L1 TAP >=1% tumors. Started Jan 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600131658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131658.